Clinical trials: Lymphoma, Malignant
Lymphoma
An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED)
This is an investigational study that increases the dosage to determine the safety/tolerability, and efficacy of a histone deacetylase inhibitor in combination with Targretin in patients with cutaneous T-cell lymphoma in patients…
- Trial name
- NCT00127101
- Testing
- vorinostat, Comparator: bexarotene
- Volunteers
- 23 people
- Sponsor
- Merck Sharp & Dohme LLC
T-cell Acute Lymphoblastic Leukemia/Lymphoma
Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL
This is an open, prospective, dose-escalation clinical study to evaluate the safety and efficacy of Senl-T7 in patients with relapsed or refractory CD7+ acute T lymphoblastic leukemia or T lymphoblastic lymphoma.Meanwhile, PK/PD…
- Trial name
- NCT05626400
- Testing
- Senl-T7
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
The main aims of this 2-part study are: Phase I: To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IDP-121 in patients with multiple myeloma (MM), diffuse large B cell lymphoma not otherwise…
- Conditions
- Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double Hit Lymphoma, High Grade B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- CASSANDRA (NCT05908409)
- Testing
- IDP-121
- Where
- 11 sites in Spain
- Volunteers
- 37 people
- Sponsor
- IDP Discovery Pharma S.L.
Lymphocytic Leukemia, Chronic, Lymphoma, Non Hodgkin
A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) administered as a single agent and in combination with atezolizumab in participants with relapsed or refractory B-cell NHL and CLL.
- Trial name
- NCT02500407
- Testing
- BTCT4465A (Mosunetuzumab) IV, Atezolizumab, BTCT4465A (Mosunetuzumab) SC
- Where
- 35 sites in United States, Australia and 5 more
- Volunteers
- 713 people
- Sponsor
- Genentech, Inc.
Indolent B-cell Non-Hodgkin's Lymphoma
Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ME-401 in the treatment of Japanese participants with Relapsed or Refractory indolent B-Cell Non-Hodgkin's Lymphoma.
- Trial name
- NCT04533581
- Testing
- ME-401
- Where
- 30 sites in Japan
- Volunteers
- 61 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Hodgkin Lymphoma
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
Researchers are looking for a way to treat classical Hodgkin lymphoma (cHL) that is relapsed (the cancer has come back after treatment) or refractory (current treatment has stopped working to slow or stop cancer growth).
- Trial name
- NCT05508867
- Testing
- favezelimab/pembrolizumab, bendamustine, gemcitabine
- Where
- 105 sites in United States, Argentina and 18 more
- Volunteers
- 203 people
- Sponsor
- Merck Sharp & Dohme LLC
B-Cell Malignancies
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
This is a Phase 2, multicenter, open-label study to provide continued supply of parsaclisib as monotherapy or in combination therapy with itacitinib, ruxolitinib, or ibrutinib to participants from Incyte-sponsored studies of…
- Trial name
- NCT04509700
- Testing
- Parsaclisib, parsaclisib + itacitinib, parsaclisib + ruxolitinib
- Where
- 105 sites in United States, Austria and 15 more
- Volunteers
- 112 people
- Sponsor
- Incyte Corporation
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia
This is an open-label, multi-dose, single-arm, Phase 1, dose-escalation study of XmAb5574. The study was conducted to identify the maximum tolerated dose (MTD) and/or recommended dose(s) (RD) for further study, to characterize…
- Trial name
- NCT01161511
- Testing
- XmAb5574
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Xencor, Inc.
Lymphoma
Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)
The purpose of this study is to assess the clinical benefit of Nivolumab, as measured by independent radiologic review committee (IRRC)-assessed objective response rate (ORR) in subjects with FL lymphoma who have failed therapy…
- Trial name
- NCT02038946
- Testing
- Nivolumab
- Where
- 45 sites in United States, Australia and 10 more
- Volunteers
- 116 people
- Sponsor
- Bristol-Myers Squibb
Non-Hodgkin's Lymphoma, Multiple Myeloma
PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation
This is an open-label, single-arm, multicentre study conducted in Spain to estimate the effectiveness of palifermin administered at a dose of 60 mg/kg/day IV for 3 consecutive days before the start of the conditioning regimen and…
- Trial name
- NCT00352703
- Testing
- Kepivance (Palifermin)
- Volunteers
- 145 people
- Sponsor
- Swedish Orphan Biovitrum
Hodgkin Disease Lymphoma
A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma
This is an open-label, multicenter, randomized, phase 3 trial to evaluate the efficacy of Penpulimab vs. standard chemotherapy selected by investigator in patients with relapsed or refractory classic Hodgkin's lymphoma.
- Trial name
- NCT05244642
- Testing
- Penpulimab, Investigator's choice of Chemotherapy
- Where
- 6 sites in China
- Volunteers
- 60 people
- Sponsor
- Akeso
B-cell Non-Hodgkin's Lymphoma
A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL
This is a Phase 1, open-label, single-arm study to evaluate tolerability, safety and efficacy of RJMty19 in adult subjects with r/r B-NHL.
- Trial name
- NCT06314828
- Testing
- RJMty19 (CD19-CAR-DNT cells)
- Volunteers
- 30 people
- Sponsor
- Guangdong Ruishun Biotech Co., Ltd
Diffuse, Large B-Cell, Lymphoma
A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients
The purpose of this study is to comparing the Efficacy and Safety between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients.
- Trial name
- NCT02867566
- Testing
- IBI301 plus CHOP, Rituximab plus CHOP
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Cancer, Lymphoma
Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)
To evaluate whether palifermin (rHuKGF) administered as a single dose is non-inferior to 3 consecutive doses of palifermin in reducing the incidence of severe oral mucositis (World Health Organization [WHO] grade 3 and 4).
- Conditions
- Cancer, Lymphoma, Leukemia
- Trial name
- NCT00109031
- Testing
- palifermin, Total Body Irradiation, Cyclophosphamide
- Volunteers
- 47 people
- Sponsor
- Swedish Orphan Biovitrum
Leukemia, B-cell, Lymphoma, B-Cell
Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted CAR-T cells therapy for patients with relapsed/refractory B Cell Leukemia and Lymphoma.
- Trial name
- NCT04648475
- Testing
- CD19 and CD22 targeted CAR-T cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Classical Hodgkin Lymphoma
Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL
To characterize safety, tolerability and to establish the maximum tolerated dose (MTD) for Tenalisib in combination with Pembrolizumab in patients with cHL.
- Trial name
- NCT03471351
- Testing
- Tenalisib, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Rhizen Pharmaceuticals SA
Advanced Solid Tumors, Lymphoma
KN046 in Subjects With Advanced Solid Tumors and Lymphoma
This is a phase Ia/Ib, open-label, multicenter, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of KN046 in subjects with advanced solid tumors and lymphoma .
- Trial name
- NCT03733951
- Testing
- KN046
- Where
- 13 sites in China
- Volunteers
- 139 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
B-Cell Lymphoma
A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas
First in human, open-label, sequential dose escalation and expansion study of CPI-1205 in patients with progressive B-cell lymphomas. CPI-1205 is a small molecule inhibitor of EZH2.
- Trial name
- NCT02395601
- Testing
- CPI-1205
- Where
- 6 sites in United States
- Volunteers
- 41 people
- Sponsor
- Constellation Pharmaceuticals
Non-Hodgkin Lymphoma Refractory/ Relapsed
Study for Participants With Relapsed/Refractory Non-Hodgkin Lymphoma
Open Label, Phase 1 study of CD19 t-haNK as a single agent and combination with rituximab in subjects with selected CD19+ and CD20+ R/R B-cell non-Hodgkin Lymphoma( NHL).
- Trial name
- NCT06334991
- Testing
- CD19 t-haNK
- Where
- 3 sites in South Africa
- Volunteers
- 20 people
- Sponsor
- ImmunityBio, Inc.
T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).
- Conditions
- T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma, Peripheral T-Cell Lymphoma, Not Classified
- Trial name
- NCT04234048
- Testing
- Fenretinide
- Where
- 10 sites in United States
- Volunteers
- 46 people
- Sponsor
- SciTech Development, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.